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Abstract
Reactivation of androgen receptor (AR) may drive recurrent prostate cancer in castrate pa-
tients. Ack1 tyrosine kinase is overexpressed in prostate cancer and promotes castrate re-
sistant xenograft tumor growth and enhances androgen target gene expression and AR
recruitment to enhancers. Ack1 phosphorylates AR at Tyr-267 and possibly Tyr-363, both in
the N-terminal transactivation domain. In this study, the role of these phosphorylation sites
was investigated by characterizing the phosphorylation site mutants in the context of full
length and truncated AR lacking the ligand-binding domain. Y267F and Y363F mutants
showed decreased transactivation of reporters. Expression of wild type full length and trun-
cated AR in LNCaP cells increased cell proliferation in androgen-depleted conditions and
increased colony formation. However, the Y267F mutant of full length and truncated AR
was defective in stimulating cell proliferation. The Y363F mutant was less severely affected
than the Y267F mutant. The full length AR Y267F mutant was defective in nuclear translo-
cation induced by androgen or Ack1 kinase. The truncated AR was constitutively localized
to the nucleus. Chromatin immunoprecipitation analysis showed that it was recruited to the
target enhancers without androgen. The truncated Y267F ARmutant did not exhibit consti-
tutive nuclear localization and androgen enhancer binding activity. These results support
the concept that phosphorylation of Tyr-267, and to a lesser extent Tyr-363, is required for
AR nuclear translocation and recruitment and DNA binding and provide a rationale for de-
velopment of novel approaches to inhibit AR activity.
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Introduction
Prostate cancer remains the second leading cause of cancer death among American men due to
the progression after androgen deprivation therapy of initially hormone dependent prostate
cancer. Current evidence indicates that reactivation of androgen receptor (AR) in tumor cells
may play a critical role in the development of castration resistant prostate cancer (CRPC) [1].
Multiple mechanisms of AR activation in CRPC tumor cells have been characterized. These in-
clude increased expression of AR mRNA, AR gene amplification, and point mutations in AR
[2–5]. Modest overexpression of AR in prostate cancer cells was sufficient to promote the cas-
trate resistant growth of xenograft tumors [2]. Furthermore, increased expression of coactiva-
tors such as SRC1 or TIF2/SRC2/NCOA2 may enhance AR transactivation [6]. Intratumoral
de novo biosynthesis of androgen in CRPC tumor cells may also provide for ligand-dependent
activation of AR [3,7,8]. Splice variants of AR lacking the ligand-binding domain have been
found to be expressed in prostate cancer cells [9–12]. Emergence of constitutively active AR
variants may mediate growth and progression of prostate cancer in the castrate host and may
confer resistance to new potent antiandrogens [13,14].
In addition, activation of AR through crosstalk with kinase signaling pathways has been
postulated as a potential mechanism for recurrent tumor growth in the castrate environment
[1]. AR protein undergoes phosphorylation at serine/threonine and tyrosine residues [15]. Guo
et al demonstrated that Src kinase-mediated phosphorylation of AR at Tyr-534 induced nucle-
ar location, recruitment of AR to the chromatin, and tumor growth in castrated animals [16].
Etk/BMX tyrosine kinase phosphorylates AR at Tyr-534 [17]. Fer tyrosine kinase, acting down-
stream of interleukin-6, phosphorylates AR at Tyr-223 [18]. Ack1 (activated cdc42-associated
kinase, also known as Tnk2) is a nonreceptor tyrosine kinase that is overexpressed in several
different tumor types, including prostate, and enhances tumor growth and invasion and metas-
tasis [19–22]. For example, ectopic expression of activated Ack1 in prostate cancer cells en-
hanced the ability of androgen-dependent prostate cancer cells to grow as xenograft tumors in
castrated animals [23]. Ack1 promoted AR target gene expression and recruitment and binding
of AR to the regulatory regions of target genes, coincident with AR tyrosine phosphorylation.
AR Tyr-267 phosphorylation by Ack1 was initially identified by mass spectroscopy and subse-
quently confirmed by phospho-specific antibodies [23–25]. AR Tyr-363 as a major Ack1-de-
pendent phosphorylation site was suggested only by mutational analysis [23]. Mutation of
these two sites in AR inhibited Ack1-induced AR transactivation and DNA binding as well as
tumor growth. However, the role of these phosphorylation sites in general AR function in pros-
tate cancer cells that have not been transfected with activated Ack1 has not been well character-
ized. In this study, the phenotype of phosphorylation site mutants of full length AR and the
constitutively active AR that lacks the ligand-binding domain was investigated.
Materials and Methods
Cell lines and reagents
LNCaP cells [26] was initially obtained from American Type Culture Collection (Manassas,
VA, catalog number CRL-1740) and were authenticated by short tandem repeat analysis per-
formed by the Tissue Culture Facility of the University of North Carolina at Chapel Hill at the
conclusion of this study. LNCaP cells were grown in phenol red-free RPMI 1640 supplemented
with 10% fetal bovine serum. COS-7 cells (ATCC, CRL-1651) were grown in DMEM supple-
mented with 10% fetal bovine serum. Epidermal growth factor (EGF) and Gas6 were purchased
from R&D Systems (Minneapolis, MN). Heregulin was a gift from Genentech (South San Fran-
cisco, CA). Phospho-Tyr-267 specific polyclonal antibody against AR was previously described
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[24]. For immunoblotting and immunofluorescence of AR, a mouse monoclonal antibody
against AR (F39.4.1, Biogenex, San Ramon, CA) was used. For immunoprecipitation of AR, a
polyclonal antibody against AR (C-19, Santa Cruz Biotechnology, Dallas, TX) was used. A
mouse monoclonal antibody against FLAG and FLAG-conjugated agarose beads (Sigma-Al-
drich, St. Louis, MO) were used for immnuoblotting and immunoprecipitation, respectively.
Rabbit polyclonal antibodies against Laminin A/C (H-110) and 14-3-3 β (C-20) (Santa Cruz)
were used in immunoblotting of subcellular fractions. Immunoblotting data shown in figures
are representative of at least three independent experiments. Donkey anti-mouse fluorescein
isothiocyanate (FITC)-labeled secondary antibody (Jackson ImmunoResearch, West Grove,
PA) and mounting media with DAPI were used for staining AR and nucleus, respectively.
Plasmids and reporter assays
For construction of AR mutants, the QuikChange Site-Directed Mutagenesis Kit (Strategene,
La Jolla, CA) was used according to the manufacturer’s protocol. A stop codon was inserted
after amino acid 660 in the wild type AR plasmid to generate the truncated AR construct. All
mutations were confirmed by sequencing. LNCaP cells were plated (1.5 X 105 cells per well) in
12-well plates the day before transfection. 150 ng of the AR construct (wild type or mutant)
and 150 ng of the AR-dependent reporter construct (MMTV- or ARR2-PB-luciferase) were
co-transfected using Effectene (Qiagen, Valencia, CA). Next day, medium was replaced with
phenol-red free, serum free media and incubated for 8 hours. Cells were then treated with 10
nM dihydrotestosterone (DHT) (Sigma-Aldrich) or vehicle in serum free media for 16 hrs. Lu-
ciferase activity was measured, as previously described [23,24].
Cell proliferation and soft agar colony formation
The AR fragments were subcloned into the pMSCV-puro retroviral vector. AR constructs con-
tain both HA and FLAG tags. LNCaP cells were engineered to stably express AR wt or mutant
AR constructs via retroviral transduction and selection as described [22]. Cells were cultured in
a 96 well plate for 72 hours in media with charcoal-stripped serum and indicated concentra-
tions of DHT. The colorimetric dye WST-8 (Dojindo, Rockville, MD) was added and absor-
bance at 450 nm was measured. Soft agar colony formation assays of LNCaP cells stably
expressing vector, AR wt, or mutant AR constructs were performed as described previously
[24].
Subcellular fractionation of protein
Subcellular fractionation of cells was performed by using NE-PER Nuclear and Cytoplasmic
Extraction Reagent (Pierce Biotechnology, Rockford, IL), supplemented with protease inhibi-
tors to cytoplasmic extraction reagent I (CER I) and nuclear extraction reagent (NER) as de-
scribed in their protocol. The protein content of cytoplasmic and nuclear extracts was
determined with the Bradford assay reagent (Bio-Rad, Hercules, CA) and an equal amount of
protein was used in immunoblotting.
Immunofluorescence
COS-7 cells were counted and 3x104 cells were plated in each well of two well chamber slides
(LabTek II System, Nalge Nunc International, Naperville, IL). Next day, cells were transiently
transfected with AR (100 ng) or vector (100 ng) along with constitutively active Ack1 (100 ng)
or vector (100 ng) expression constructs, using FuGENE 6 (Roche Applied Science, Indianapo-
lis, IN) and incubated for overnight. Media was changed to serum free medium and cells were
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serum starved for 8 hrs. After serum starvation, cells were either treated with DHT (10 nM) or
vehicle (1% ethanol) for 2 hours. Next, media was removed from the cells and cells were rinsed
with cold phosphate buffered saline (PBS) once for 5 minutes. The fixative (4% paraformalde-
hyde) was added to the cells and incubated at room temperature for 15 minutes. At the end of
the fixation, cells were washed with cold PBS twice, and the blocking solution (0.3% Triton X
and 5% donkey serum) was added and incubated for 30 minutes at room temperature. At the
end of the incubation, blocking solutions were removed from the wells except the blank sam-
ples. Primary antibody, mouse anti-androgen receptor (F39.4.1, Biogenex, San Ramon, CA)
made in 1:100 dilution in the blocking solution, was added on the cells and incubated at room
temperature for two hour. At the end of incubation, primary antibody was removed from the
cells and the cells were washed three times with cold PBS (5 minutes each wash). Secondary an-
tibody, FITC-conjugated donkey anti mouse antibody, was prepared in 1:250 dilution in the
blocking solution and added to the cells. The cells were incubated in the dark at 37°C for one
hour. The secondary antibody was removed and the cells were washed with cold PBS three
times. At the end of the wash, cover slips were placed with the mounting media which includes
4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA) for nuclear
staining. After cover slips were mounted, slides were kept in the dark cold room until images
were captured.
Chromatin immunoprecipitation
Chromatin immunoprecipitation analysis for recruitment of FLAG-tagged AR protein to the
androgen response element III enhancer of canonical AR target genes, prostate specific antigen
(PSA) and kallikrein-related peptidase 2 (KLK2), was performed as previously described [23].
mRNA levels of PSA and KLK2 by quantitative RT-PCR was determined as previously de-
scribed [23].
Microarray gene expression analysis and AR pathway score
Total RNA from LNCaP cells expressing vector, TR-WT-AR, and TR-AR-Y267F growing in
androgen deprived conditions were isolated by using RNeasy Mini kit (Qiagen Inc., Valencia,
CA) according to the manufacturer’s instructions. Two biological replicates were used per each
cell line. RNA integrity was evaluated using the RNA 6000 Nano LabChip kit and a Bioanalyzer
(Agilent Technologies Inc., Santa Clara, CA). RNA samples from TR-AR-WT or
TR-AR-Y267F were assayed versus vector control as reference sample. The samples were hy-
bridized onto the Agilent Whole Human Genome Oligonucleotide Microarray (4X44K) ac-
cording to the manufacturer’s protocol at the UNC Genomics Core Facility. The microarrays
were scanned on an Agilent scanner and the raw data extracted and deposited into the UNC
Microarray Database. Individual channel values were background corrected and lowess nor-
malized. The resulting log ratios were median centered by gene to produce the values for fur-
ther gene expression analysis. From microarray gene expression data, a score representing AR
transcription pathway activity was calculated. The previously published androgen response sig-
nature was used [27]. This signature is composed of genes that increase or decrease in response
to androgen. For each sample, a t-statistic between the normalized expression of the genes ex-
pected to increase versus those expected to decrease in response to androgen was calculated as
previously described [28]. A positive score indicates increased activation of the AR transcrip-
tion pathway while a negative score indicates decreased activation of the pathway.
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Statistical analysis
The two-group t-test was used for the pair-wise group comparisons of wt to Y267F and wt to
Y363F. These t-test p values have been adjusted using the Bonferroni method to account for
multiple testing. Statistical analyses were performed with SAS statistical software (Version 9.2,
SAS Institute Inc., Cary, NC). p value<0.05 was considered statistically significant.
Results
Ligand-independent AR activation is impaired in phosphorylation site
mutants of truncated AR
AR-dependent reporter assays showed impaired ligand-dependent and Ack1-induced activa-
tion of full length AR when Tyr-267 and Tyr-363 residues were mutated to phenylalanine [23].
To assess the role of these phosphorylation sites in ligand-independent AR activation, the
phosphorylation site mutants Y267F and Y363F were tested in the context of truncated AR
containing amino acid 1–660 (out of 919 amino acids of full length AR). This truncated AR
protein retains the N-terminal transactivation domain and the central DNA binding domain.
However, it is missing the C-terminal ligand-binding domain and is constitutively active in the
absence of ligand [29]. The truncated AR bearing the Y267F mutation exhibited marked reduc-
tion in its ability to activate both MMTV and ARR2-PB reporters (Fig 1A and 1B). The Y363F
mutant also showed decreased transcriptional activity, but to a less extent. Immunoblotting
confirmed that protein levels of truncated AR withY267F and Y363F mutations were similar to
that of wild type truncated AR (Fig 1C), although all three truncated AR proteins were express-
ed at lower levels than full length AR. Taken together, these results suggest that Tyr-267 and
possibly Tyr-363 are essential for both ligand-dependent and-independent transcriptional ac-
tivity of AR, and that loss of Tyr-267 exhibits more severe impairment of transcriptional func-
tion, compared to Tyr-363.
Stably overexpressed wild type full length AR and truncated AR proteins
are phosphorylated at Tyr-267 after growth factor treatment
Overexpression of AR in androgen-dependent LNCaP cells enhances cell proliferation at sub-
optimal androgen concentrations [2,30]. The functional role of AR Tyr-267 and Tyr-363 sites
in the cellular context was investigated by stable overexpression of wild type and mutant AR
constructs. The total protein levels of full length AR in LNCaP cells stably expressing exoge-
nous AR by retroviral transduction was 2–3 fold higher than endogenous AR in vector control
cells (Fig 2A). Detection of exogenous AR by the epitope tag verified that wild type, Y267F, and
Y363F AR were all expressed at comparable levels. In cells expressing truncated AR constructs,
levels of wild type, Y267F, and Y363F AR migrating at about 80 kDa were similar (Fig 2C). AR
mRNA levels in stably overexpressing cells were 3–4 folds higher than vector control cells in
full length AR-expressing cells and 2–3 folds higher in truncated AR-expressing cells (Fig 2B
and 2D). Immunoblotting with the phospho-Tyr-267 AR specific antibody demonstrated that
both full length and truncated exogenous AR proteins were phosphorylated at Tyr-267 after
stimulation with EGF, heregulin, or Gas6, as previously shown for endogenous AR protein
[24] and that phosphorylation of Tyr-267 is not detected in Y267F AR protein (Fig 3). Muta-
tion of Tyr-363 did not affect phosphorylation of Tyr-267.
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Phosphorylation site mutants of AR are defective in stimulating cell
proliferation and anchorage-independent soft agar colony growth
The effect of AR overexpression on cell proliferation at various androgen concentrations was
characterized. Proliferation of vector control cells was androgen-dependent and required the
full dose (10 nM) of DHT for optimal proliferation (Fig 4A). Full length AR wt overexpressing
cells exhibited increased proliferation in the absence of androgen and maximal proliferation at
0.1 nM DHT, a concentration that did not stimulate proliferation of vector control cells.
Fig 1. Phosphorylation site mutants of constitutively active truncated AR lacking the ligand-binding
domain exhibit impaired transcriptional function in reporter assays. (A, B) LNCaP cells were transiently
transfected with vector alone or the expression vector encoding full-length AR wt, truncated AR wt
(TR-AR-WT), Y267F or Y363F mutants of truncated AR along with the AR-dependent reporter MMTV-
luciferase (A) or ARR2-PB-luciferase (B). After 48 hours in androgen depleted media, luciferase activity was
determined from cell lysates. Data shown with the mean + standard deviation of triplicate samples are
representative of three independent experiments with similar results. *, p<0.001 vs TR-AR-WT; **, p<0.05 vs
TR-AR-WT by two-group t-test adjusted using the Bonferroni method. (C) Cell lysates of COS-7 cells
transiently transfected with respective AR constructs were immunoblotted with the monoclonal antibody
against AR.
doi:10.1371/journal.pone.0126270.g001
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However, Y267F mutant AR-expressing cells did not show increased proliferation in the ab-
sence of androgen and did not respond to increasing concentrations of androgen. Proliferation
of Y363F mutant AR-expressing cells was intermediate between vector control and AR wt cells
in the absence of androgen or at 0.1 nM DHT; the cells did not respond to increasing androgen
concentrations. Cells expressing constitutively active truncated AR proliferated optimally with-
out androgen (Fig 4B) and addition of DHT did not increase proliferation. However, cells
Fig 2. LNCaP cells stably overexpress full length or truncated AR or phosphorylation site mutants. LNCaP cells stably overexpressing AR constructs
or vector control were derived by retrovirus-mediated transduction and antibiotic selection. (A) Lysates from LNCaP cells overexpressing full-length AR were
subjected to immunoprecipitation with the AR antibody, followed by immunoblotting with the AR antibody or the epitope tag HA antibody, as indicated. Total
cell lysates were also immunoblotted with the ARmonoclonal antibody and actin antibody. (B) The mRNA levels of AR was determined by quantitative
reverse transcription PCR of total RNA isolated from LNCaP cells stably overexpressing full-length AR. (C) Lysates from LNCaP cells stably overexpressing
truncated AR were subjected to immunoprecipitation, followed by immunoblotting, as indicated. Total cell lysates were also immunoblotted with the AR
monoclonal antibody and the actin antibody. (D) The mRNA levels of AR was determined by quantitative reverse transcription PCR of total RNA isolated from
LNCaP cells stably overexpressing truncated AR.
doi:10.1371/journal.pone.0126270.g002
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Fig 3. Exogenous AR stably expressed in LNCaP cells is phosphorylated at Tyr-267 after growth factor treatment. (A, B) LNCaP cells stably
overexpressing full length AR were treated with EGF (100 ng/ml) or heregulin (10 ng/ml) or Gas6 (100 ng/ml) for 1 hr, as indicated. Cell lysates were
subjected to immunoprecipitation with the FLAG antibody, followed by immunoblotting with the phospho-specific AR or total AR antibody. (C, D) LNCaP cells
stably overexpressing truncated AR were treated with EGF (100 ng/ml) or heregulin (10 ng/ml) or Gas6 (100 ng/ml) for 1 hr, as indicated. Cell lysates were
subjected to immunoprecipitation with the FLAG antibody, followed by immunoblotting with the phospho-specific AR or total AR antibody.
doi:10.1371/journal.pone.0126270.g003
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expressing the truncated AR with the Y267F mutation did not show androgen-independent
proliferation and did not respond to androgen treatment. Cells expressing the truncated AR
with the Y363F mutation showed modest reduction in androgen-independent proliferation,
compared to AR wt and androgen treatment did not increase its growth. The effect of AR over-
expression and the effect of phosphorylation site mutation on anchorage-independent growth
in soft agar were determined for both full length and truncated AR. Overexpression of full
length or truncated AR wt significantly increased soft agar colony formation, compared to vec-
tor control cells (Fig 4C and 4D). Overexpression of the Y267F mutant of full length AR or
truncated AR demonstrated marked reduction in soft agar colony formation, compared to AR
wt. The Y363F AR-expressing showed moderately decreased soft agar colonies, but not to the
extent that the Y267F mutant did. These results suggest that the ability of AR to enhance cell
proliferation at low androgen concentrations and stimulate anchorage-independent growth in
LNCaP cells requires intact phosphorylation sites. Mutation of Tyr-267 exhibits more severe
Fig 4. Phosphorylation site mutants of AR are defective in stimulating cell proliferation and anchorage-independent soft agar colony growth. (A, B)
LNCaP cells stably overexpressing full length AR (A) or truncated AR (B) were grown in a 96-well plate for 72 hours in media with charcoal-stripped serum
and 0, 0.1, 1, or 10 nM of DHT, as indicated. Absorbance at 450 nm was measured after incubation with the colorimetric dyeWST-8 for 4 hours. Values were
normalized to vector control cells treated with 0 nM DHT. Data shown are the mean + standard deviation of three independent experiments, each performed
with triplicate or quadruplicate wells. *, p<0.001 vs AR-WT; **, p<0.05 vs AR-WT by two-group t-test adjusted using the Bonferroni method. (C, D) Cells
stably overexpressing full length AR (C) or truncated AR (D) were plated in soft agar and incubated for 3 weeks. Colonies were stained and counted. A
representative view of the colonies is shown below. Data shown are the mean + standard deviation of two (C) or three (D) independent experiments with
triplicate samples. *, p<0.001 vs AR-WT; **, p<0.05 vs AR-WT by two-group t-test adjusted using the Bonferroni method.
doi:10.1371/journal.pone.0126270.g004
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impairment than Tyr-363 in these assays. Collectively, these data suggest that the Tyr-267 and
Tyr-363 sites are both required for the full cellular effect of overexpressed AR protein.
The Y267F mutant of AR is defective in nuclear translocation
Binding of AR to its ligand causes translocation into the nucleus and binding to the promoter
and enhancer regions of its target genes. A previous report indicated that AR nuclear transloca-
tion was induced by phosphorylation of AR at Tyr-534 site by Src tyrosine kinase [16]. The ef-
fect of Ack1 kinase expression without or with DHT treatment on subcellular localization of
AR in COS-7 cells was investigated. Cytoplasmic and nuclear proteins were isolated and
probed with an AR antibody. Without DHT treatment, transfected full length AR wt localized
mostly in the cytoplasm in cells co-transfected with an empty vector control. However, Ack1
co-expression by transfection increased the amount of AR protein in the nuclear fraction (Fig
5A). In both vector and Ack1 co-transfected with AR wt, there was nuclear translocation in re-
sponse to DHT treatment. However, DHT treatment or Ack1 co-expression or both
DHT-Ack1 together did not induce the nuclear translocation of the AR Y267F mutant to the
same extent as AR wt. The nuclear localization pattern of FL-AR-Y363F was similar to AR wt.
Immunofluorescence staining of transfected COS-7 cells for AR confirmed that Ack1-induced
nuclear localization of AR was inhibited by mutating AR Tyr-267 (Fig 6). These data suggest
that AR Tyr-267 is essential for Ack1-induced AR nuclear translocation. Next, the effect of
phosphorylation sites on the nuclear localization of truncated AR was evaluated in COS-7 cells.
Truncated AR wt in the absence of DHT was localized in the nucleus to a greater extent than
full length AR (Fig 5B), as previously reported [29]. The nuclear localization of truncated
AR-Y267F was decreased in comparison to wt and the AR Y363F mutant was similar to wt (Fig
5B).
In order to confirm the role of Tyr-267 in cells that express endogenous AR, we investigated
subcellular localization of exogenous AR protein stably overexpressed in LNCaP cells by
immunoprecipitation with the FLAG epitope antibody and immunoblotting with an AR anti-
body. Overexpression of both full length and truncated AR wt induced predominantly nuclear
localization of AR even without DHT treatment (Fig 7A and 7B). The extent of nuclear locali-
zation of the Y267F mutant of AR was decreased, compared to AR wt. The Y363F mutant of
AR exhibited a pattern of nuclear localization similar to AR wt.
Y267F mutation inhibits recruitment and DNA binding of truncated AR to
the androgen responsive enhancers and transcription of target genes
To characterize the effect of Y267F and Y363F mutations on recruitment and binding of AR to
the regulatory sequences of target genes, chromatin immunoprecipitation analysis for AR bind-
ing to the enhancers of the canonical AR target genes, PSA and KLK2, was performed using
the FLAG antibody for detecting the ectopically expressed AR. Truncated AR wt protein was
constitutively bound to the PSA and KLK2 enhancers in the absence of androgen. The Y267F
mutant did not bind to the PSA and KLK2 enhancers (Fig 8A and 8B). The Y363F mutant also
showed decreased binding although the reduction is smaller as that of Y267F. In cells express-
ing truncated AR wt, PSA and KLK2 mRNA levels measured by quantitative RT-PCR were ele-
vated in the androgen deprived media. However, PSA and KLK2 mRNA levels were decreased
in cells expressing truncated AR-Y267F in comparison to AR-wt and to a less extent, in cells
expressing truncated AR-Y363F (Fig 8C and 8D). In addition to these two canonical AR target
genes, expression of AR responsive genes in these cells under androgen deprived conditions
was globally assessed by microarray gene expression analysis. The score representing the AR
transcriptional pathway activity was calculated using a published androgen response signature
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Fig 5. The AR Y267Fmutant is defective in androgen- and Ack1-induced nuclear translocation. (A)
COS-7 cells were transfected with the AR expression vector and the constitutively active Ack1 L487F
expression vector [22] and incubated for 48 hrs. The cells were serum-starved overnight and treated with or
without DHT (10 nM) for 2 hrs. Subcellular fractionation was performed. Fifteen μgrams of protein from
cytoplasmic (C) and nuclear (N) fractions were immunoblotted with the AR antibody. Laminin A/C and 14-3-3
βwere used as markers of nuclear and cytoplasmic fractions, respectively. (B) COS-7 cells were transfected
Androgen Receptor Tyr-267 Phosphorylation Is Required
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[27]. The AR pathway score was increased in cells expressing truncated AR wt and decreased
in cells expressing truncated AR-Y267F (Fig 8E). Together, these results suggested that muta-
tion of the Tyr-267 site diminishes the recruitment and DNA binding of constitutively active
truncated AR and transcription of AR responsive genes.
Discussion
In this study, the potential functional significance of the N-terminal phosphorylation sites Tyr-
267 and Tyr-363 in ligand-dependent and—independent activation of AR was investigated by
characterizing the effect of tyrosine to phenylalanine substitution mutants in the context of full
length and truncated AR. Expression of wild type full length and truncated AR led to increased
cell proliferation in the androgen-depleted condition and increased soft agar colony formation.
However, the Y267F mutant of full length and truncated AR was defective in stimulating cell
proliferation in both androgen-depleted and androgen-supplemented conditions. The Y363F
mutant was less severely affected than the Y267F mutant. The full length AR Y267F mutant
was defective in nuclear translocation induced by androgen or Ack1 kinase activity. The trun-
cated AR protein used in this study translocated to the nucleus and bound to the androgen en-
hancers of target genes in the androgen-depleted condition. However, the truncated Y267F AR
mutant protein did not exhibit constitutive nuclear localization and enhancer binding activity.
Similar to full length AR [24], the truncated AR protein was phosphorylated at Tyr-267 by
growth factor-induced activation of intracellular tyrosine kinases (Fig 3). In the previous re-
port, Ack1-induced phosphorylation of AR at Tyr-267 was linked to activation of full length
AR and xenograft tumor growth in castrated animals; expression of the full length AR Y267F
mutant inhibited Ack1-driven, castrate resistant xenograft tumor growth [23]. In this study,
with the AR expression vector (full length or truncated) and incubated for 48 hrs. Subcellular fractionation and
immunoblotting were performed as described above.
doi:10.1371/journal.pone.0126270.g005
Fig 6. Nuclear translocation of AR induced by Ack1 kinase is defective in the AR Y267Fmutant.COS-7 cells were transfected with the AR expression
vector and the constitutively active Ack1 expression vector and incubated for 48 hrs. Cells were fixed and AR expression detected with the ARmonoclonal
antibody and FITC-conjugated secondary antibody. Nuclear staining was performed with DAPI. Original magnifications, 1,000X.
doi:10.1371/journal.pone.0126270.g006
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the requirement for the Tyr-267 site even in the constitutively active truncated AR protein,
which does not require androgen, has been demonstrated. Inhibition of nuclear translocation,
binding to the androgen enhancers, and stimulating cell proliferation in the androgen-depleted
condition was observed when the truncated AR Y267F mutant was expressed. Additionally,
Fig 7. The AR Y267Fmutant is defective in nuclear localization in LNCaP cells. (A) LNCaP cells stably
overexpressing vector or AR constructs were grown in phenol red free media and serum starved for overnight
and treated with or without 10 nM DHT for 2 hrs. Cell fractionation was performed. The cytoplasmic and
nuclear lysates from LNCaP cells expressing full length AR constructs were subjected to immunoprecipitation
with FLAG antibody, followed by immunoblotting with AR antibody, as indicated. Laminin A/C and 14-3-3 β
were used as markers of nuclear and cytoplasmic fractions, respectively. (B) The cytoplasmic and nuclear
lysates from LNCaP cells stably expressing truncated AR constructs under androgen-deprived conditions
were subjected to immunoprecipitation with FLAG antibody, followed by immunoblotting with AR antibody, as
indicated. Laminin A/C and 14-3-3 βwere used as markers of nuclear and cytoplasmic fractions, respectively.
doi:10.1371/journal.pone.0126270.g007
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Fig 8. Constitutive recruitment to the chromatin of truncated AR protein and transcription of AR responsive genes are impaired by the Y267F
mutation. (A, B) LNCaP cells expressing truncated AR constructs were grown in phenol red free media supplemented with charcoal-stripped serum.
Chromatin immunoprecipitation analysis for binding of FLAG-tagged truncated AR protein to the androgen response element III enhancer region of PSA (A)
and KLK2 (B) genes were performed. The amount of precipitated DNA was determined by quantitative PCR. The data shown are the mean and standard
deviation of three independent experiments performed in triplicate. *, p<0.001 vs TR-AR-WT by two-group t-test adjusted using the Bonferroni method. (C, D)
mRNA levels of PSA and KLK2 from LNCaP cells expressing truncated AR constructs under androgen-deprived conditions as above were determined by
quantitative RT-PCR performed in triplicate. The data shown are representative of two independent experiments. *, p<0.001 vs TR-AR-WT; **, p<0.05 vs
TR-AR-WT by two-group t-test adjusted using the Bonferroni method. (E) Microarray gene expression analysis from LNCaP cells expressing truncated AR
constructs under androgen-deprived conditions using vector control as reference was performed. The AR transcriptional pathway activity score was
calculated using an established androgen response signature [27]. The score from two independent samples is shown. A positive score indicates increased
activation of the AR transcription pathway while a negative score indicates decreased activation of the pathway.
doi:10.1371/journal.pone.0126270.g008
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cells expressing the Y267F mutant of both full length and truncated AR do not exhibit andro-
gen-stimulated cell proliferation. This finding is consistent with the notion that Y267F func-
tions as a “dominant negative”mutant. Ligand-activated AR protein binds to the DNA as a
homodimer [31]. Binding between full length AR protein and the truncated AR splice variant
protein has been reported [12,32]. Therefore, it may be hypothesized that a complex of endoge-
nous wild type AR and the exogenous Y267F mutant AR is nonfunctional and inhibits the nor-
mal cellular response to androgen stimulation. In a similar manner, expression of the
ARΔ142–337 transgene with amino acids 142–337 deleted also functioned as a dominant nega-
tive mutant in CRPC cells; this construct inhibited CWR-R1 tumor growth [33]. The report by
Titus et al and the current data, taken together, support the concept that the AR domain sur-
rounding the Tyr-267 site and phosphorylation of Tyr-267 are required for AR transactivation
function, although the mechanisms involved in the dominant negative activity of ARΔ142–337
and the Y267F point mutation may differ.
Since the N-terminal transactivation domain of the AR protein is unstructured and disor-
dered [34], the detailed three-dimensional structure of this AR region has not been determined.
Therefore, the effect of Tyr-267 phosphorylation or the Y267F mutation on conformation of
the AR molecule is unknown. The AR protein at this residue and other phosphorylation sites
likely undergoes rapid cycles of phosphorylation and dephosphorylation and this transient
phosphorylation, below the limits of detection by conventional techniques, may be required for
optimal AR function. The interaction with components of nuclear import and export machin-
ery as well as coactivators and the basal transcriptional complex may be regulated by phos-
phorylation at Tyr-267 and potentially Tyr-363. The finding that AR phosphorylated at Tyr-
267 may be recruited to enhancers that are distinct from enhancers bound by androgen ligand-
activated AR is consistent with this idea that phosphorylation of AR at Tyr-267 adds an addi-
tional level of regulation for AR activity. AR phosphorylated at Tyr-267 has been shown to be
recruited to the upstream regulatory region of the ATM gene and enhance its expression [35].
Sites such as Tyr-534, targeted by Src and Etk/BMX kinases, and some serine/threonine sites
(i.e. Ser-81 and Ser-650) may be involved as well. The AR protein phosphorylated by Src at
Tyr-534 localizes to the nucleus in androgen-depleted conditions and the phenotype of the
Y534F mutant of full length AR resembles that of the Y267F mutant of full length AR described
in the current study [16]. Ser-81 of AR is phosphorylated by cyclin-dependent kinase 1 and 9
[36,37]. Chen et al recently demonstrated through expression of the S81A mutant in LNCaP
cells that Ser-81 phosphorylation is required for ligand-induced AR recruitment to the andro-
gen enhancers and transcription of target genes [38]. The ligand-activated S81A mutant was lo-
calized predominantly in the cytoplasm and chromatin immunoprecipitation analysis showed
decreased binding of the S81A AR to the androgen enhancers. The AR bound to chromatin
was shown to be phosphorylated on Ser-81. Another group showed that the S81A AR mutant
inhibited LNCaP cell proliferation and considered the S81A mutant to exhibit dominant nega-
tive activity [39]. The published phenotype of the S81A mutant parallels that of the Y267F mu-
tant described in this study. The stress kinases JNK and p38 regulate the nuclear export of AR
by phosphorylation of AR at Ser-650 [40]. Protein phosphatase 1 (PP1) associates with AR and
regulates AR transcriptional activity and nuclear localization through dephosphorylation of
Ser-650 [41]. Interestingly, a germline mutation S650G of AR results in the mild androgen in-
sensitivity syndrome associated with male infertility and moderately reduced reporter transac-
tivation in vitro [42]. This incomplete loss of function of the S650G mutant may stem from
loss of phosphorylation at this site. In addition to phosphorylation, other post-translational
modifications, such as acetylation, ubiquitination, and SUMOylation, regulate AR function;
there may well be crosstalk between phosphorylation and these other modifications [15,43].
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There has been much interest in the AR splice variants expressed in tumor cells that are sim-
ilar in structure to the truncated AR used in this study. These AR splice variants may play a
role in progression to castrate resistance and acquired resistance to new therapeutic agents. AR
splice variants retain the N-terminal transactivation domain and the DNA binding domain but
lack the ligand-binding domain [9–12]. However, it should be noted that the truncated AR
1–660 used in this study differs from naturally occurring AR splice variants in several aspects.
The AR 1–660 construct contains most of the hinge region encoded in exon 4 and therefore,
the bipartite nuclear localizing signal (NLS) remains intact. However, most of AR variants do
not contain exon 4 and the complete bipartite NLS [44]. ARv567es, a major splice variant com-
monly expressed in clinical tumor specimens, does contains the bipartite NLS [12]. The C-ter-
minus of AR splice variants differs from the AR 1–660 construct by the addition of short
variable peptide sequences [44]. Presently, the contribution of these C-terminal sequences on
the function of AR splice variants has not been elucidated yet. Because of these structural dif-
ferences between the AR 1–660 and AR splice variants, the requirement for Tyr-267 phosphor-
ylation in naturally occurring AR splice variants requires further investigation.
Two recently approved prostate cancer drugs abiraterone and enzalutamide target the li-
gand-binding domain of AR by decreasing the ligand availability or inhibiting binding of the li-
gand. These agents extend the overall survival of CRPC patients by approximately four or five
months [45,46]. While these effects are substantial, most patients develop resistance to these
drugs and die from progressive prostate cancer. The rise in the PSA level, which may signal AR
reactivation in tumor cells, occurs after a median of 8–10 months of treatment. Data from pre-
clinical model systems suggest that emergence of AR splice variants lacking the ligand-binding
domain may mediate resistance to enzalutamide and abiraterone [13,14]. Therefore, a new
class of drugs is needed to target AR variants without the ligand-binding domain. The finding
that loss of phosphorylation sites in the N-terminal domain of AR leads to inhibition of AR ac-
tivity provides a rationale for development of novel approaches to inhibit AR splice variants.
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